Evidence-Based Positron Emission Tomography : : Summary of Recent Meta-Analyses on PET.

• Author: Treglia, Giorgio.
• TeilnehmendeR: Giovanella, Luca.
• Place / Publishing House: Cham : : Springer International Publishing AG,, 2020.; ©2020.
• Year of Publication: 2020
• Edition: 1st ed.
• Language: English
• Physical Description: 1 online resource (138 pages)

Table of Contents

• Intro
• Preface
• Contents
• Part I: Introduction
• 1: Introduction to Different PET Radiopharmaceuticals and Hybrid Modalities (PET/CT and PET/MRI)
• 1.1 Physical Principles of Positron Emission Tomography and Hybrid Modalities
• 1.2 Hybrid Scanners: PET/CT and PET/MRI
• 1.3 Positron Emission Tomography Radiopharmaceuticals
• References
• 2: A Practical Guideline on Diagnostic and Prognostic Meta-Analyses
• 2.1 Introduction
• 2.2 A Clear Topic for Systematic Review: Formulating the Question
• 2.3 Which Articles Should Be Included? Search Strategy, Inclusion and Exclusion Criteria
• 2.4 Quality Assessment of the Included Studies
• 2.5 Data Extraction
• 2.6 Pooling Diagnostic Indices Across Studies and Reporting Heterogeneity
• 2.7 Discussion and Conclusion of Systematic Reviews
• 2.8 Final Comment
• References
• Part II: Evidence-Based PET in Oncology
• 3: Evidence-Based PET for Brain Tumours
• 3.1 Background
• 3.2 Evaluation of Suspicious Primary Brain Tumour
• 3.2.1 18F-FDG
• 3.2.2 11C-Methionine
• 3.2.3 18F-FET
• 3.2.4 18F-FDOPA
• 3.3 Glioma Grading
• 3.3.1 18F-FDG
• 3.3.2 11C-Methionine
• 3.3.3 18F-FET
• 3.3.4 18F-FDOPA
• 3.4 Delineation of Gliomas
• 3.5 Diagnosis of Recurrent Brain Tumours
• 3.5.1 18F-FDG
• 3.5.2 11C-Methionine
• 3.5.3 18F-FET
• 3.5.4 18F-FDOPA
• 3.5.5 18F-FLT
• 3.5.6 18C-Choline
• 3.6 Diagnosis of Brain Metastases
• 3.7 Diagnosis of Recurrent Brain Metastases
• 3.8 Diagnosis of Primary Central Nervous System Lymphoma (PCNSL)
• 3.9 Prognostic Value in Patients with Glioma
• 3.10 Conclusions
• References
• 4: Evidence-Based PET for Head and Neck Tumours
• 4.1 Introduction
• 4.2 Staging
• 4.2.1 T Staging
• 4.2.2 Nodal and Distant Metastases Detection
• 4.3 Prognostic Value
• 4.4 Post-treatment Evaluation.
• 4.5 Carcinoma of Unknown Origin and Incidental Findings
• References
• 5: Evidence-Based PET for Thoracic Tumours
• 5.1 Introduction
• 5.2 Evidence-Based Data on PET in Primary Lung Tumours
• 5.2.1 Characterization of Solitary Pulmonary Nodules (SPNs)
• 5.2.1.1 Single-Time-Point 18F-FDG PET or PET/CT
• 5.2.1.2 Dual-Time-Point (DTP) PET
• 5.2.1.3 18F-FLT PET for Evaluation of Pulmonary Lesions
• 5.2.2 NSCLC Staging
• 5.2.2.1 N Staging
• 5.2.2.2 M Staging
• 5.2.3 Restaging After Induction Therapy and Prediction of Treatment Response
• 5.2.4 Radiation Therapy Pretreatment Planning in NSCLC
• 5.2.5 Diagnosis of Lung Cancer Recurrence
• 5.2.6 Prognostic Evaluation in NSCLC
• 5.2.7 Management of SCLC
• 5.3 Evidence-Based Data on PET in Pleural Tumours
• 5.4 Evidence-Based Data on PET in Thymic Epithelial Tumours
• 5.5 Evidence-Based Data on PET in Esophageal Tumours
• 5.5.1 Staging
• 5.5.2 Restaging
• 5.5.3 Predictive and Prognostic Value
• References
• 6: Evidence-Based PET for Breast Cancer
• 6.1 Introduction
• 6.2 Staging
• 6.3 Restaging and Assessment of Response to Neoadjuvant Therapy
• 6.4 Prognostic Value
• 6.5 Incidental 18F-FDG Uptake
• 6.6 18F-FDG Positron Emission Mammography
• 6.7 PET/MRI
• 6.8 Other PET Tracers Beyond 18F-FDG
• References
• 7: Evidence-Based PET for Abdominal and Pelvic Tumours
• 7.1 Introduction
• 7.2 PET in Gastrointestinal Tumours
• 7.2.1 Colorectal Cancer
• 7.2.2 Gastric Cancer
• 7.2.3 Anal Cancer
• 7.2.4 Stromal Tumours (GIST)
• 7.2.5 Hepato-biliary Tumours
• 7.2.6 Liver Metastases
• 7.2.7 Pancreatic Cancer
• 7.3 PET in Gynaecological Tumours
• 7.3.1 Cervical Cancer
• 7.3.2 Endometrial Cancer
• 7.3.3 Ovarian Cancer
• 7.3.4 Peritoneal Carcinomatosis
• 7.3.5 PET/MRI
• 7.4 PET in Uro-genital Tumours
• 7.4.1 Prostate Cancer.
• 7.4.1.1 Radiolabelled Choline PET for Prostate Cancer
• 7.4.1.2 Radiolabelled PSMA PET in Prostate Cancer
• 7.4.1.3 Fluciclovine PET in Prostate Cancer
• 7.4.1.4 Incidental 18F-FDG Uptake in the Prostate
• 7.4.2 Bladder Cancer
• 7.4.3 Renal Cell Carcinoma
• 7.4.4 Testicular and Penile Cancer
• References
• 8: Evidence-Based PET for Cutaneous, Musculoskeletal and Unknown Primary Tumours
• 8.1 Introduction
• 8.2 PET in Malignant Melanoma
• 8.2.1 Introduction
• 8.2.2 Staging
• 8.2.3 Restaging and Treatment Monitoring
• 8.3 PET in Sarcomas
• 8.3.1 Introduction
• 8.3.2 Staging
• 8.3.3 Restaging and Treatment Monitoring
• 8.4 PET for Bone Metastases
• 8.4.1 Introduction
• 8.4.2 Detection of Bone Metastases
• 8.5 PET for Cancer of Unknown Primary (CUP) and Paraneoplastic Syndromes
• 8.5.1 Introduction
• 8.5.2 Impact of PET in Patients with CUP
• 8.5.3 Impact of PET in Patients with Paraneoplastic Syndromes
• References
• 9: Evidence-Based PET for Haematological Tumours
• 9.1 Introduction
• 9.2 18F-FDG PET or PET/CT in Staging or Detection
• 9.2.1 Post-transplant Lymphoproliferative Disorder
• 9.2.2 Follicular Lymphoma
• 9.2.3 Marginal Zone Lymphoma of the Mucosa-Associated Lymphoid Tissue
• 9.2.4 Bone Marrow Involvement in Lymphoma
• 9.2.5 Natural Killer/T-Cell Lymphoma
• 9.2.6 Multiple Myeloma
• 9.3 18F-FDG PET or PET/CT in Treatment Response Evaluation (Interim and/or End of Therapy)
• 9.3.1 Post-transplant Lymphoproliferative Disorder
• 9.3.2 Hodgkin and Non-Hodgkin Lymphomas
• 9.4 18F-FDG PET or PET/CT in Prognosis/Outcome Evaluation
• 9.4.1 Hodgkin and Non-Hodgkin Lymphomas
• 9.4.2 Multiple Myeloma
• 9.5 Prognostic Role of Semi-quantitative PET Parameters
• 9.6 18F-FDG PET or PET/CT in Comparison with Magnetic Resonance Imaging
• 9.7 Conclusions
• References.
• 10: Evidence-Based PET for Endocrine Tumours and Disorders
• 10.1 Introduction
• 10.2 Adrenal Tumours and Paragangliomas
• 10.2.1 Characterization of Adrenal Masses
• 10.2.2 Paragangliomas
• 10.3 Neuroblastoma
• 10.4 Merkel Cell Carcinoma
• 10.5 Gastroenteropancreatic and Pulmonary Neuroendocrine Tumours
• 10.6 Congenital Hyperinsulinism
• 10.7 Thyroid Diseases
• 10.7.1 Thyroid Incidentalomas
• 10.7.2 Indeterminate Thyroid Nodules
• 10.7.3 Recurrence of Differentiated Thyroid Cancer
• 10.7.4 Recurrence of Medullary Thyroid Cancer
• 10.8 Parathyroid Diseases
• References
• Part III: Evidence-Based PET in Cardiology
• 11: Evidence-Based PET for Cardiac Diseases
• 11.1 Introduction
• 11.2 Myocardial Blood Flow Perfusion
• 11.2.1 Performance of PET/CT in the Assessment of Myocardial Perfusion in Comparison to Other Myocardial Perfusion Imaging Modalities
• 11.2.2 Prognostic Value of Myocardial PET
• 11.3 Assessment of Myocardial Viability
• 11.4 Microvascular Disease
• 11.5 Cardiac Hybrid Imaging
• 11.6 Cardiac Amyloidosis
• References
• Part IV: Evidence-Based PET in Infection and Inflammation
• 12: Evidence-Based PET for Infectious and Inflammatory Diseases
• 12.1 Introduction
• 12.2 Fever of Unknown Origin (FUO)
• 12.3 Large Vessel Vasculitis (LVV)
• 12.4 Infectious Endocarditis and Cardiovascular Implantable Electronic Device Infections
• 12.5 Vascular Graft Infections
• 12.6 Sarcoidosis
• 12.7 Musculoskeletal Infections
• 12.8 Inflammatory Rheumatic Diseases
• 12.9 Inflammatory Bowel Diseases
• References
• Part V: Evidence-Based PET in Neurology
• 13: Evidence-Based PET for Neurological Diseases
• 13.1 Introduction
• 13.2 Evidence-Based PET in Neurodegenerative Dementia
• 13.3 Evidence-Based PET for Movement Disorders
• 13.4 Evidence-Based PET for Psychiatric Disorders.
• 13.5 Conclusions
• References
• Part VI: Miscellaneous
• 14: Meta-Analyses on Technical Aspects of PET
• 14.1 Introduction
• 14.2 Factors Affecting 18F-FDG Uptake
• 14.3 Repeatability of the Quantitative Measurements
• 14.4 Dual-Time-Point Imaging
• 14.5 Correlation Between Proliferation Markers (Ki-67) and Tracer Uptake in Tumours
• 14.6 Correlation Between 18F-FDG SUVmax and ADC Values in Tumour Tissues
• 14.7 Diagnostic Performance of Hybrid Imaging in Oncology
• 14.8 Varia
• References.